Table 3.
Comparison with data from The COVID-19 Global Rheumatology Alliance Global Registry.
| Meta-analysis | Global Registry | |
|---|---|---|
| Female % | 64% | 76% |
| Rheumatoid arthritis | 33.7% | 38.4% |
| Spondyloarthritisa | 22.0% | 15.5% |
| Systemic Lupus Erythematosus | 14.3% | 20.7% |
| Vasculitis | 5.5% | 5.6% |
| Inflammatory myopathy | 5.2% | 2.4% |
| Sjogren syndrome | 3.3% | 3.8% |
| Systemic sclerosis | 1.7% | 3.4% |
| Gout | 0% | 2.4% |
| Othersb | 14.4% | 5.7% |
| Hospitalized | 56% | 33% |
| Death | 7.0% | 6.7% |
a
Merged data of spondyloarthritis and psoriatic arthritis in the COVID-19 Global Rheumatology Alliance Global Registry.
b
: merged data of other inflammatory arthritis, sarcoidosis and undifferentiated connective tissue disease in the COVID-19 Global Rheumatology Alliance Global Registry (accessed on 13rd November 2020).